Latest News and Press Releases

VERAXA Biotech Strengthens Patent Portfolio to Protect Core Technology Platforms and Product Candidates

VERAXA Biotech's and OmniAb's bispecific ADC program VXA-222 advances into next phase at VERAXA following the achievement of a key technical milestone.

ZURICH, SWITZERLAND , July 24, 2026 (GLOBE NEWSWIRE) -- VERAXA Biotech AG (NASDAQ: VRXA; “VERAXA”), an emerging leader in the design and development of next-generation cancer therapeutics, held an...

ZURICH, SWITZERLAND, July 23, 2026 (GLOBE NEWSWIRE) -- VERAXA Biotech AG (NASDAQ: VRXA; “VERAXA”), an emerging leader in designing novel cancer therapies, today announced the appointment of...

VERAXA has received Scientific Advice from the Paul-Ehrlich-Institute providing an initial derisking of the development path of its BiTAC-TCE program.

VERAXA Biotech initiates a collaboration with Ardigen SA to optimize cancer target pair selection for growing BiTAC® pipeline.

ZURICH, May 20, 2025 (GLOBE NEWSWIRE) -- VERAXA Biotech AG (“VERAXA”), an emerging leader in designing novel cancer therapies and proposed de-SPAC acquisition target of Voyager Acquisition Corp....